Literature DB >> 22909324

De novo membranous nephropathy (MN) in kidney allografts. A peculiar form of alloimmune disease?

Claudio Ponticelli1, Richard J Glassock.   

Abstract

De novo membranous nephropathy (MN) is an uncommon complication of kidney transplantation, which shows histological findings similar to those seen in recurrent MN, but with some distinct differences. The clinical presentation may be variable, from asymptomatic to nephrotic proteinuria. The disease may run an indolent course or may have an accelerated course leading to allograft loss. De novo membranous nephropathy (MN) can develop in transplant recipients with viral hepatitis, Alport syndrome, ureteral obstruction, renal infarction, or in conjunction with recurrent IgA nephritis. Histologic signs of allograft rejection are often associated with or can antedate de novo MN. These findings suggest that donor-specific antibodies and antibody-mediated rejection might play a pathogenetic role in some patients with de novo MN. However, signs of rejection were absent in a number of cases, and in some instances the disease developed in recipients of "full house" HLA- matched kidneys. Thus, it seems possible that de novo MN is not because of allograft rejection per se, but is triggered by different injuries that can create an inflammatory environment, activate innate immunity, and expose hidden (cryptic) antigens, probably different from those observed to be involved in idiopathic MN. These events can lead to the production of circulating antibodies and in situ formation of immune complexes (IC) and the morphological lesion of MN.
© 2012 The Authors. Transplant International © 2012 European Society for Organ Transplantation.

Entities:  

Mesh:

Year:  2012        PMID: 22909324     DOI: 10.1111/j.1432-2277.2012.01548.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  9 in total

Review 1.  Membranous Nephropathy: A Journey From Bench to Bedside.

Authors:  Jean M Francis; Laurence H Beck; David J Salant
Journal:  Am J Kidney Dis       Date:  2016-04-13       Impact factor: 8.860

2.  A Case of De Novo Membranous Nephropathy Causing Renal Transplant Rejection.

Authors:  Sarah C Kurkowski; Michael J Thimmesch; Amro Abdelghani; Yasir H Abdelgadir
Journal:  Cureus       Date:  2022-06-23

3.  Relapsing De Novo Membranous Nephropathy.

Authors:  Ala Ali; Huda Al-Taee; Thaer J Kadhim
Journal:  Case Rep Transplant       Date:  2022-05-02

Review 4.  De novo glomerular diseases after renal transplantation.

Authors:  Claudio Ponticelli; Gabriella Moroni; Richard J Glassock
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 8.237

Review 5.  De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases?

Authors:  Fedaey Abbas; Mohsen El Kossi; Jon Kim Jin; Ajay Sharma; Ahmed Halawa
Journal:  World J Transplant       Date:  2017-12-24

6.  HLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy.

Authors:  Jiqiu Wen; Kenan Xie; Mingchao Zhang; Jinsong Chen; Jiong Zhang; Dongrui Cheng; Xue Li; Shuming Ji; Zhihong Liu
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

7.  The utility of phospholipase A2 receptor autoantibody in membranous nephropathy after kidney transplantation.

Authors:  Marc Xipell; Lida M Rodas; Jesús Villarreal; Alicia Molina; Johanna Reinoso-Moreno; Miquel Blasco; Esteban Poch; Fritz Diekmann; Jose M Campistol; Luis F Quintana
Journal:  Clin Kidney J       Date:  2017-11-22

Review 8.  Recurrent and de novo Glomerulonephritis After Kidney Transplantation.

Authors:  Wai H Lim; Meena Shingde; Germaine Wong
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

9.  Is de novo membranous nephropathy suggestive of alloimmunity in renal transplantation? A case report.

Authors:  Prakash I Darji; Himanshu A Patel; Bhavya P Darji; Ajay Sharma; Ahmed Halawa
Journal:  World J Transplant       Date:  2022-01-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.